Last reviewed · How we verify
Diclofenac sodium and safinamide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Diclofenac sodium and safinamide (Diclofenac sodium and safinamide) — Zambon SpA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diclofenac sodium and safinamide TARGET | Diclofenac sodium and safinamide | Zambon SpA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diclofenac sodium and safinamide CI watch — RSS
- Diclofenac sodium and safinamide CI watch — Atom
- Diclofenac sodium and safinamide CI watch — JSON
- Diclofenac sodium and safinamide alone — RSS
Cite this brief
Drug Landscape (2026). Diclofenac sodium and safinamide — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-sodium-and-safinamide. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab